Mark Zobeck

ORCID: 0000-0003-0997-906X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Lymphoblastic Leukemia research
  • Childhood Cancer Survivors' Quality of Life
  • Blood groups and transfusion
  • Lymphoma Diagnosis and Treatment
  • Platelet Disorders and Treatments
  • Sarcoma Diagnosis and Treatment
  • Blood Coagulation and Thrombosis Mechanisms
  • Cancer-related cognitive impairment studies
  • Chronic Lymphocytic Leukemia Research
  • Cardiac Arrhythmias and Treatments
  • CNS Lymphoma Diagnosis and Treatment
  • Adolescent and Pediatric Healthcare
  • Cancer-related molecular mechanisms research
  • COVID-19 Clinical Research Studies
  • Venous Thromboembolism Diagnosis and Management
  • Renal and related cancers
  • Oral health in cancer treatment
  • Cardiovascular Issues in Pregnancy
  • Viral-associated cancers and disorders
  • Blood properties and coagulation
  • Atrial Fibrillation Management and Outcomes
  • Hematopoietic Stem Cell Transplantation
  • Retinal and Optic Conditions
  • Renal Diseases and Glomerulopathies
  • Complement system in diseases

Texas Children's Hospital
2019-2025

Baylor College of Medicine
2019-2025

Children's Cancer Center
2020-2024

While rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents, past epidemiology studies of this malignancy used data that covered <30% US population. Therefore, we evaluated RMS incidence using from U.S. Cancer Statistics (USCS) survival trends National Program Registries (NPCR), which covers 100% 94% population, respectively.Incidence were assessed for pediatric patients diagnosed with during 2003-2017 2001-2016, respectively. Both demographic clinical...

10.1002/cam4.5211 article EN Cancer Medicine 2022-09-07

Abstract Methotrexate is a critical component of curative chemotherapy for pediatric acute lymphoblastic leukemia (ALL), but associated with neurotoxicity. Information on long‐term outcomes following an neurotoxic event limited. Therefore, this report compares neurocognitive performance more than 12 months post diagnosis (mean = 4 years) between ALL patients ( n 25) and without 146) history Compared to children no documented on‐treatment event, who experienced during treatment exhibited...

10.1002/pbc.31169 article EN Pediatric Blood & Cancer 2024-07-03

PURPOSE Molecular markers increasingly influence risk-stratified treatment selection for pediatric rhabdomyosarcoma (RMS). This study aims to integrate molecular and clinical data produce individualized prognosis predictions that can further improve selection. METHODS Clinical variables somatic mutation 20 genes from 641 patients with RMS in the United Kingdom States were used develop three Cox proportional hazard models predicting event-free survival (EFS). The Baseline (BC) model included...

10.1200/po-24-00556 article EN JCO Precision Oncology 2025-02-01

Abstract Background High‐dose methotrexate (HD‐MTX; 5000 mg/m 2 ) is an important component of curative therapy in many treatment regimens for high‐risk pediatric acute lymphoblastic leukemia (ALL). However, can result dose‐limiting neurotoxicity, which may disproportionately affect Latino children. This study evaluated risk factors neurotoxicity after HD‐MTX ethnically diverse population patients with ALL. Methods The authors retrospectively reviewed the medical records who were diagnosed...

10.1002/cncr.34646 article EN Cancer 2023-01-24

Abstract Introduction Wilms tumor therapy in low‐ and middle‐income countries (LMICs) relies on treatment protocols adapted to resource limitations, but these have rarely been evaluated real‐world settings. Such evaluations are necessary identify high‐impact research priorities for clinical implementation trials LMICs. The purpose of this study was highest priority targets future sub‐Saharan Africa by assessing outcomes a resource‐adapted protocol Malawi. Methods We conducted retrospective...

10.1002/pbc.30242 article EN Pediatric Blood & Cancer 2023-02-16

Abstract Study Objective Methotrexate (MTX) is a key component of treatment for high‐risk pediatric acute lymphoblastic leukemia (ALL) but may cause kidney injury and prolonged hospitalization due to delayed clearance. The purpose this study identify clinical genetic factors that predict which children are at risk creatinine increase MTX Design We conducted single‐center, retrospective cohort patients with ALL who received 4000–5000 mg/m 2 MTX. Measurements performed germline genotyping...

10.1002/phar.2779 article EN Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy 2023-02-11

(2020). Hispanic ethnicity is associated with prolonged clearance of high dose methotrexate and severe nephrotoxicity in children adolescents acute lymphoblastic leukemia. Leukemia & Lymphoma: Vol. 61, No. 11, pp. 2771-2774.

10.1080/10428194.2020.1783445 article EN Leukemia & lymphoma/Leukemia and lymphoma 2020-07-01

Abstract Background Carboxypeptidase G 2 (CPDG ; glucarpidase) is a rescue drug for patients at risk kidney injury from high‐dose methotrexate (MTX). As there are no strategies predicting who will require CDPG , we evaluated the role of demographic, clinical, and genetic factors CPDG use. Procedure Cases received controls did not were identified by chart review acute lymphoblastic leukemia (ALL) MTX doses between 1000 5000 mg/m 2010 2017. We used multivariable Bayesian logistic regression to...

10.1002/pbc.29036 article EN Pediatric Blood & Cancer 2021-03-31

Ablation for atrioventricular nodal reentrant tachycardia (AVNRT) classically utilizes evaluation of signal morphology within the anatomic region slow pathway (SP), which involves subjectivity. Ripple mapping (RM; CARTO-3© Biosense Webster Inc) displays each electrogram at its three-dimensional coordinate as a bar changing in length according to voltage-time relationship. This allows prolonged, low-amplitude signals be displayed their entirety, helping identify propagation low-voltage areas....

10.1111/jce.15491 article EN Journal of Cardiovascular Electrophysiology 2022-04-14

Diagnosing von Willebrand Disease (VWD) in adolescent females is challenging as menstruation and physiologic stress elevate factor (VWF) laboratory values.

10.1111/hae.14865 article EN Haemophilia 2023-09-18

Objective To describe the incidence, clinical characteristics, and long-term outcomes of cerebral sinus venous thrombosis in children with acute lymphoblastic leukemia. Methods This was a retrospective cohort study comprising pediatric patients newly diagnosed or first-relapse leukemia who developed at Texas Children's Hospital from 2002 to 2019. Results Nineteen cases (1.7%) were identified all (n = 1129). Increased risk observed age &gt;10 years ( P .006). Twelve (63%) occurred during...

10.1177/08830738241282910 article EN Journal of Child Neurology 2024-09-26

Delayed excretion of high-dose methotrexate (HD-MTX) in pediatric acute lymphoblastic leukemia (ALL) can result significant morbidity. While is primarily renally excreted, HD-MTX may overwhelm renal and increase reliance on fecal elimination. This study evaluated the association between laxative use for constipation delayed HD-MTX.

10.1002/pbc.31377 article EN cc-by-nc Pediatric Blood & Cancer 2024-10-10

Kaposi sarcoma (KS) is a common lymphatic endothelial cancer among children with and without HIV in central eastern Africa. Despite its clinical heterogeneity, various phenotypes are often grouped together staging treatment algorithms. Patients KS tumor-associated edema, referring to hard, non-pitting lesions which lead chronic disability, represent unique, understudied subgroup of KS. To continue our work defining the distinct pediatric KS, this study aimed assess progression outcomes edema...

10.3390/cancers16223769 article EN Cancers 2024-11-08

Abstract Background Methotrexate is an important component of curative therapy in childhood acute lymphoblastic leukemia (ALL), but the role genetic variation influencing methotrexate clearance and transport toxicity susceptibility children with ALL not well established. Therefore, we evaluated association between suspected pharmacogenomic variants methotrexate‐related neurotoxicity. Methods This study included (aged 2–20 years) diagnosed (2005–2019) at six treatment centers southwest United...

10.1002/phar.4638 article EN Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy 2024-12-29

There is emerging evidence of microvascular thrombosis and thrombotic microangiopathy (TMA) induced by COVID-19, presumably from endothelial injury. Thrombomodulin (TM) an glycoprotein that plays a dual role in maintaining healthy endothelium-as natural anticoagulant binding thrombin to activate protein C (APC) negative regulator the alternate complement pathway (AP). TM shed into plasma as soluble (sTM) during We hypothesize SARS-CoV-2 spike proteins cause direct injury, leading shedding,...

10.1016/j.tru.2022.100116 article EN cc-by-nc-nd Thrombosis Update 2022-07-08

CHG-based hygiene methods are often a component of daily bundles to prevent central line-associated blood stream infections (CLABSIs) in pediatric hematology-oncology patients; however, adherence with 2% CHG wipes was inconsistent within our institution, risking infection for immunocompromised patients. A new 4% foam method offers an alternative and is applied while bathing, as opposed used 1 h after bathing. An initial cohort 24 high-risk oncology bone marrow transplant (BMT) patients...

10.1080/08880018.2022.2090644 article EN Pediatric Hematology and Oncology 2022-07-15

Abstract Purpose Wilms tumor is a common renal cancer of childhood with long-term survival rates exceeding 80% in high-resource countries, yet remains below 50% the low-resource settings Africa. We assessed outcomes resource-adapted treatment protocol at Malawian hospital to identify actionable factors affecting survival. Methods clinical single-center retrospective cohort study children diagnosed between 2016 and 2021 Lilongwe, Malawi. Findings identified 136 patients tumor, most commonly...

10.1101/2022.08.08.22278537 preprint EN medRxiv (Cold Spring Harbor Laboratory) 2022-08-09
Coming Soon ...